Celldex Therapeutics, Inc. (CLDX) vs Progyny, Inc. (PGNY)
A side-by-side comparison of Celldex Therapeutics, Inc. and Progyny, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLDX
Celldex Therapeutics, Inc.
$30.97HealthcareDelayed quote: Oct 6, 2026, 1:05 PM EDT
PGNY
Progyny, Inc.
$26.01HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
Total return — CLDX vs PGNY
growth of $100 · dividends reinvested · last 7yCLDX +1304.7% (+45.9%/yr)PGNY +62.2% (+7.2%/yr)CLDX compounded faster over this window
Log scale — wide-divergence pair
CLDX PGNY
CLDX vs PGNY: by the numbers
- •CLDX is the larger company ($2.06B vs $2.04B market cap).
- •PGNY is profitable (6.00% net margin) while CLDX runs a net loss (-268385.71%).
- •PGNY grew revenue faster over the past five years (23.84% vs -58.05% CAGR).
Metrics side by side
Valuation
| Metric | CLDX | PGNY |
|---|---|---|
| P/E ratio | N/A | 28.27 |
| Forward P/E | N/A | 20.22 |
| PEG ratio | N/A | 4.22 |
| P/S ratio | 18398.12 | 1.55 |
| P/B ratio | 2.88 | 4.50 |
| EV / EBITDA | N/A | 16.02 |
| FCF yield | N/A | 10.70% |
Profitability
| Metric | CLDX | PGNY |
|---|---|---|
| Gross margin | 100.00% | 24.57% |
| Operating margin | -19160.00% | 8.55% |
| Net margin | -268385.71% | 6.00% |
| ROE | -42.07% | 17.35% |
| ROIC | -45.19% | 15.47% |
Growth (annualized)
| Metric | CLDX | PGNY |
|---|---|---|
| Revenue CAGR (5Y) | -58.05% | 23.84% |
| EPS CAGR (5Y) | N/A | 4.72% |
| FCF CAGR (5Y) | N/A | 73.48% |
| Total return CAGR (5Y) | -10.28% | -14.83% |
Frequently asked
- Which has grown faster, CLDX or PGNY?
- Over the past five years, PGNY grew revenue faster — CLDX at a -58.05% CAGR versus PGNY at 23.84%.
- Is CLDX or PGNY more profitable?
- PGNY runs the higher net margin — CLDX at -268385.71% versus PGNY at 6.00%.
- How have CLDX and PGNY total returns compared?
- Over the past 5 years, CLDX delivered -10.28% and PGNY delivered -14.83% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Progyny P/E ratioCelldex Therapeutics ROEProgyny ROECelldex Therapeutics operating marginProgyny operating marginCelldex Therapeutics revenue growthProgyny revenue growthCelldex Therapeutics free cash flowProgyny free cash flow
Celldex Therapeutics & Progyny appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.